Chemotherapy Regimens for Newly Diagnosed Metastatic Gastric Cancer
First-Line Treatment Selection
For newly diagnosed metastatic gastric cancer, your chemotherapy regimen must be selected based on HER2 status, PD-L1 expression (CPS score), and MSI/dMMR status—these biomarkers are mandatory before starting any treatment.
Treatment Algorithm by Biomarker Status:
HER2-Positive Disease (IHC 3+ or IHC 2+/FISH+) with PD-L1 CPS ≥1:
Pembrolizumab + trastuzumab + fluoropyrimidine (5-FU or capecitabine) + platinum (cisplatin or oxaliplatin) is the preferred first-line regimen 1. This quadruplet combination achieved median OS of 20 months versus 16.9 months with chemotherapy plus trastuzumab alone in KEYNOTE-811, with improved response rates (72.6% vs 59.8%) 1. This is FDA-approved and represents a Category 1 recommendation.
- If PD-L1 CPS <1: Use trastuzumab + cisplatin + fluoropyrimidine (capecitabine or 5-FU) without immunotherapy 2, 1
HER2-Negative Disease with PD-L1 CPS ≥5:
Pembrolizumab + fluoropyrimidine + platinum-based chemotherapy is the preferred Category 1 regimen 1. The KEYNOTE-859 trial demonstrated median OS of 15.7 months versus 11.8 months with chemotherapy alone in the PD-L1 CPS ≥10 subgroup (HR 0.65, P <0.0001) 1.
- For PD-L1 CPS 1-4: Pembrolizumab + chemotherapy is still preferred but with slightly less robust benefit (median OS 13 vs 11.4 months) 1
- For PD-L1 CPS <1: Use chemotherapy alone (fluoropyrimidine + platinum doublet)
MSI-H/dMMR Tumors (Any Line):
Pembrolizumab monotherapy should be the first choice 2, 1. The KEYNOTE-158 trial showed unprecedented ORR of 45.8% and median PFS of 11 months with pembrolizumab monotherapy in MSI-H gastric cancer—results never achieved with chemotherapy 2. This represents a paradigm shift where immunotherapy alone outperforms chemotherapy.
HER2-Negative, PD-L1 Low/Negative, MSS:
Use fluoropyrimidine + platinum doublet chemotherapy. Common regimens include:
- FOLFOX (5-FU + oxaliplatin)
- CAPOX (capecitabine + oxaliplatin)
- Cisplatin + 5-FU or capecitabine
Three-drug combinations (adding docetaxel or epirubicin) increase response rates but also toxicity without substantial survival benefit when second-line therapy is available 3.
Baseline Investigations Required Before Starting Chemotherapy
Mandatory Biomarker Testing:
- HER2 status (IHC and FISH if IHC 2+): Essential for trastuzumab eligibility. Patients with IHC 3+ or IHC 2+/FISH+ derive maximum benefit (median OS 16 vs 11.8 months with trastuzumab) 1
- PD-L1 CPS score: Required for pembrolizumab decision-making. CPS ≥5 represents the strongest evidence for benefit 1
- MSI/dMMR status: Identifies patients who should receive pembrolizumab monotherapy instead of chemotherapy 2, 1
Staging and Extent of Disease:
- High-resolution CT chest, abdomen, and pelvis: Assess metastatic burden and identify oligometastatic disease 4
- Video-documented upper endoscopy with biopsy: Confirm diagnosis and obtain tissue for biomarker testing 4
- Endoscopic ultrasound: If locally advanced features or uncertain resectability 4
- Consider diagnostic laparoscopy if peritoneal metastases suspected but not confirmed on imaging
Organ Function and Performance Status:
- Complete blood count: Assess for anemia, neutropenia, thrombocytopenia
- Comprehensive metabolic panel: Liver function (AST, ALT, bilirubin, alkaline phosphatase), renal function (creatinine, eGFR), electrolytes
- ECOG performance status: Must be 0-2 for most chemotherapy regimens
- Cardiac function: Baseline echocardiogram or MUGA scan if planning trastuzumab (monitor LVEF)
- Nutritional assessment: Weight, albumin, prealbumin—early nutritional support improves outcomes 5
Additional Baseline Tests:
- Hepatitis B and C screening: Required before immunotherapy
- Pregnancy test: For women of childbearing potential
- Tumor markers: CEA, CA 19-9 (optional, for monitoring response)
Second-Line Treatment Options
If first-line therapy fails:
Ramucirumab + paclitaxel is the preferred second-line regimen 2. The RAINBOW trial demonstrated improved OS, PFS, and ORR with this combination versus paclitaxel alone 2.
Alternative second-line options include:
- Ramucirumab monotherapy (REGARD trial showed OS benefit but limited response rates) 2
- FOLFIRI (limited data) 2
- Taxane or irinotecan monotherapy 2
For MSI-H tumors progressing after chemotherapy, pembrolizumab remains highly effective in second-line 2.
Third-Line Treatment
Trifluridine/tipiracil has the strongest evidence from the phase III TAGS trial 2. Alternative options include taxane or irinotecan if not previously used 2.
For HER2-positive disease progressing on trastuzumab, trastuzumab deruxtecan showed survival benefit in phase II trials 2.
Critical Pitfalls to Avoid
- Do not start any chemotherapy without HER2, PD-L1, and MSI testing—you will miss opportunities for highly effective targeted/immune therapy
- Do not use pembrolizumab in MSI-H patients with chemotherapy—monotherapy is superior 2
- Do not assume all metastatic disease is incurable—oligometastatic patients may benefit from conversion therapy after excellent response to systemic therapy, though this remains investigational 2
- Do not delay early supportive care—symptom management and nutritional support are associated with 3-month survival benefit 5
- Verify cardiac function before trastuzumab—cardiotoxicity monitoring is mandatory